

Docket No. 27693-01013

U.S. Patent Application No. 08/921,060

**Listing of the Claims**

1-23. (Canceled)

24. (Currently amended) A method of inducing B cell depletion in a patient ~~in need of such depletion~~ having a B cell disorder comprising administering a B cell depleting effective amount of a non-radiolabeled chimeric anti-CD20 antibody, wherein said chimeric anti-CD20 antibody ~~wherein when~~ administered by itself at a dosage of 0.4 mg/kg body weight results in ~~merely complete B-cell~~ depletion of greater than 90% of peripheral B cells within about 24 ~~hour~~ hours post treatment infusion of said chimeric anti-CD20 antibody.

25-30. (Canceled)

31. (Original) The method of claim 24 wherein said chimeric anti-CD20 antibody contains the variable heavy sequence corresponding to SEQ ID NO: 11.

32. (Original) The method of claim 24 wherein said chimeric anti-CD20 antibody contains the variable light sequence corresponding to SEQ ID NO: 7.

33. (Original) The method of claim 24 which further includes the administration of at least one chemotherapeutic agent.

34. (Original) The method of claim 33 wherein said at least one chemotherapeutic agent is selected from the group consisting of cyclophosphamide, doxorubicin, vincristine and prednisone.

35-40. (Canceled)

Docket No. 27693-01013

U.S. Patent Application No. 08/921,060

41. (Original) The method of claim 24 which further includes the administration of a radiolabeled anti-CD20 antibody.
42. (Original) The method of claim 41 wherein said radiolabeled anti-CD20 antibody is a murine anti-CD20 antibody.
43. (New) The method of claim 24 wherein said chimeric anti-CD20 antibody contains the variable heavy sequence corresponding to SEQ ID NO: 11 and the variable region light sequence corresponding to SEQ ID NO: 7, or CD20 binding fragment thereof.
44. (New) The method of claim 24 wherein said chimeric anti-CD20 antibody contains the complementarity determining regions of SEQ ID NOs: 7 and 11.